# BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS

> **NCT02351635** · — · COMPLETED · sponsor: **Bühlmann Laboratories AG** · enrollment: 478 (actual)

## Conditions studied

- Inflammatory Bowel Disease
- Irritable Bowel Syndrome

## Interventions

- **OTHER:** fecal calprotectin level

## Key facts

- **NCT ID:** NCT02351635
- **Lead sponsor:** Bühlmann Laboratories AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2018-03
- **Final completion:** 2018-04
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2019-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02351635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02351635, "BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02351635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*